GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein

Cell Death and Differentiation

Volumn 22, Issue 5, 2015, Pages 838-851

  Credle, J J ^a   George, J L ^b   Wills, J ^a   Duka, V ^a   Shah, K ^a   Lee, Y C ^a   Rodriguez, O ^a   Simkins, T ^c   Winter, M ^a   Moechars, D ^d   Steckler, T ^d   Goudreau, J ^c   Finkelstein, D I ^b   Sidhu, A ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c East Lansing   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE; TAU PROTEIN;

ANIMAL; GENETICS; HUMAN; METABOLISM; MOUSE; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MICE, TRANSGENIC; PARKINSONIAN DISORDERS; TAU PROTEINS;

EID: 84939985495     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.179     Document Type: Article

References (70)

1. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283.
2. Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R et al. Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for parkinson's disease. Mov Disord 2011; 26: 819-823.
3. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW et al. Genome-wide association study confirms SNPs in SNCA and the MAPTregion as common risk factors for Parkinson disease. Ann Hum Genet 2010; 74: 97-109.
4. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
5. Yasuda T, Nakata Y, Mochizuki H. a-Synuclein and neuronal cell death. Mol Neurobiol 2013; 47: 466-483.
6. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012; 124: 325-338.
7. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol 2002; 4: 160-164.
8. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739-29752.
9. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005; 8: 657-663.
10. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of a-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 2010; 183: 115-145.
11. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62: 389-397.
12. Duka V, Lee JH, Credle J, Wills J, Oaks A, Smolinsky C et al. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One 2013; 8: e75025.
13. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated taupathy and alphasynuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
14. Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ et al. Confluence of a-Synuclein, Tau, and β-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 2013; 72: 1203-1212.
15. Muntané G, Dalfó E, Martinez A, Ferrer I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha synucleinopathies. Neuroscience 2008; 152: 913-923.
16. Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009; 23: 2820-2830.
17. Wills J, Credle J, Oaks AW, Duka V, Lee JH, Jones J et al. Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways. Plos One 2012; 7: e30745.
18. Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP] and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 2011; 286: 5055-5068.
19. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A. Tauopathic changes in the striatum of A53T a-synuclein mutant mouse model of Parkinson's disease. Plos One 2011; 6: e17953.
20. Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E et al. Hyperphosphorylated Tau in an a-synuclein overexpressing transgenic model of Parkinson's disease. Eur J Neurosci 2011; 33: 1598-1610.
21. Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL et al. The significance of a-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis 2014; 13: 154-156.
22. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al. Parkinson's Progression Markers InitiativeAssociation of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and a-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013; 70: 1277-1287.
23. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of a-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 2013; Sep; 14: 626-636.
24. Ciaccioli G, Martins A, Rodrigues C, Vieira H, Calado P. A powerful yeast model to investigate the synergistic interaction of a-synuclein and tau in neurodegeneration. PLoS One 2013; 8: e55848.
25. Lin CH, Tsai PI, Wu RM, Chien CT. LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3beta. J Neurosci 2010; 30: 13138-13149.
26. Kawakami F, Shimada N, Ohta E, Kagiya G, Kawashima R, Maekawa T et al. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β. FEBS J 2014; 281: 3-13.
27. Hernandez F, Lucas JJ, Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J Alzheimers Dis 2013; 33: S141-S144.
28. Hanger DP, Noble W. Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011: 352805.
29. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-255.
30. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperonedependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 2006; 24: 627-633.
31. Ilouz R, Pietrokovski S, Eisenstein M, Eldar-Finkelman H. New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta. J Mol Biol 2008; 383: 999-1007.
32. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-1384.
33. Yost C, Farr GH 3rd, Pierce SB, Ferkey DM, Chen MM, Kimelman D. GBP an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 1998; 93: 1031-1041.
34. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I et al. Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 2010; 143: 1136-1148.
35. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011; 41: 508-527.
36. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Serapide MF et al. Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease. Stem Cells 2014; 32: 2147-2163.
37. Gómez-Sintes R, Hernández F, Bortolozzi A, Artigas F, Avila J, Zaratin P et al. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice. EMBO J 2007; 26: 2743-2754.
38. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27-39.
39. Gordon JW, Chesa PG, Nishimura H, Rettig WJ, Maccari JE, Endo T et al. Regulation of Thy-1 gene expression in transgenic mice. Cell 1987; 50: 445-452.
40. Mayford M, Wang J, Kandel ER, O'Dell TJ. CaMKII regulates the frequency-response function of hippocampal synapses for the production of both LTD and LTP. Cell 1995; 81: 891-904.
41. Petit-Paitel A, Brau F, Cazareth J, Chabry J. Involment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP+-treated neurons. PLoS One 2009; 4: e5491.
42. Hongo H, Kihara T, Kume T, Izumi Y, Niidome T, Sugimoto H et al. Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Biochem Biophys Res Commun 2012; 426: 94-99.
43. Spittaels K, Van den Haute C, Van Dorpe J, Terwel D, Vandezande K, Lasrado R et al. Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience 2002; 113: 797-808.
44. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2011; 10: 1108-1118.
45. Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 2013; 80: 857-864.
46. Ziegler DA, Wonderlick JS, Ashourian P, Hansen LA, Young JC, Murphy AJ et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol 2013; 70: 241-247.
47. Lundblad M, Decressac M, Mattsson B, Björklund A. Impaired neurotransmission caused by overexpression of a-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 2012; 109: 3213-3219.
48. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415-455.
49. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976; 38: 277-301.
50. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1993; 13: 290-296.
51. Hornykiewicz O. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv Neurol 1990; 60: 140-147.
52. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45: 1292-1299.
53. Kalinderi K, Fidani L, Katsarou Z, Clarimón J, Bostantjopoulou S, Kotsis A. GSK3β polymorphisms, MAPT H1 haplotype and Parkinson's disease in a Greek cohort. Neurobiol Aging 2011; 32: 546.e1-5.
54. Wider C, Vilariño-Güell C, Heckman MG, Jasinska-Myga B, Ortolaza-Soto AI, Diehl NN et al. SNCA, MAPT, and GSK3B in Parkinson disease: a gene-gene interaction study. Eur J Neurol 2011; 18: 876-881.
55. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD et al. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58: 829-839.
56. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. Glycogen synthase kinase 3beta (beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004; 18: 1162-1164.
57. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, Tamura K et al. Stimulatory effect of a-synuclein on the tau-phosphorylation by GSK-3β. FEBS J 2011; 278: 4895-4904.
58. Chau KY, Ching HL, Schapira AH, Cooper JM. Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 2009; 110: 1005-1013.
59. Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M et al. Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 2007; 85: 1819-1825.
60. Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 2012; 4: pii: a008771.
61. L'episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Morale MC et al. AWnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener 2011; 6:49
62. Marchetti B, L'Episcopo F, Morale MC, Tirolo C, Testa N, Caniglia S et al. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci 2013; 37: 1550-1563.
63. Fricke ST, Rodriguez O, Vanmeter J, Dettin LE, Casimiro M, Chien CD et al. In Vivo Magnetic Resonance Volumetric and Spectroscopic Analysis of Mouse Prostate Cancer Models. Prostate 2006; 66: 708-717.
64. Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC et al. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle 2012; 11: 3801-3809.
65. Oaks AW, Frankfurt M, Finkelstein DI, Sidhu A. Age-dependent effects of A53T alphasynuclein on behavior and dopaminergic function. PLoS One 2013; 8: e60378.
66. Finkelstein DI, Stanic D, Parish CL, Drago J, Horne MK. Quantified assessment of terminal density and innervation. Curr Protoc Neurosci 2004 Chapter 1:Unit 1.13.
67. Sperber BR, Leight S, Goedert M, Lee VM. Glycogen synthase kinase-3 beta phosphorylates tau protein at multiple sites in intact cells. Neurosci Lett 1995; 197: 149-153.
68. Rodríguez-Martín T, Cuchillo-Ibáñez I, Noble W, Nyenya F, Anderton BH, Hanger DP. Tau phosphorylation affects its axonal transport and degradation. Neurobiol Aging 2013; 34: 2146-2157.
69. Gil-Loyzaga P, Parés-Herbute N. HPLC detection of dopamine and noradrenaline in the cochlea of adult and developing rats. Brain Res Dev Brain Res 1998; 48: 157-160.
70. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA et al. Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem 2008; 283: 16895-16905.